Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
This study has been completed.
Study NCT00502112 Information provided by Seattle Genetics, Inc.
First Received on July 13, 2007. Last Updated on October 7, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelodysplastic Syndrome (MDS)
Additional conditions recognized in this trial
More general conditions related to this trial
Bone Marrow Diseases
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Angiogenesis Modulating Agents
Physiological Effects of Drugs
Sponsors listed in this trial
Seattle Genetics, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers